MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, DMAC had -$783K decrease in cash & cash equivalents over the period. -$6,566K in free cash flow.

Cash Flow Overview

Change in Cash
-$783K
Free Cash flow
-$6,566K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Total operating expenses, excluding share-based compensation
8,017 -
Total share-based compensation
1,016 -
Operating loss
-9,033 -
Interest income
440 -
Other income (expense), net
-21 -
Income tax expense
6 -
Net loss
-8,620 -15,406
Share-based compensation
1,016 1,638
Amortization of discounts on marketable securities
249 441
Non-cash lease expense
21 40
Depreciation
18 14
Amounts receivable
99 -75
Prepaid expenses and other assets
-235 453
Deposits
0 -1,108
Accounts payable
659 321
Accrued liabilities and operating lease liabilities
469 -1,643
Net cash used in operating activities
-6,550 -14,747
Purchase of marketable securities
34,854 16,370
Maturities and sales of marketable securities
9,104 31,967
Purchase of property and equipment
16 18
Net cash provided by (used in) investing activities
-25,766 15,579
Proceeds from the sale of common shares, net of offering costs
31,527 0
Proceed from the exercise of common stock options
465 257
Deferred offering costs
456 -
Principal payments on finance lease obligations
3 5
Net cash provided by financing activities
31,533 252
Net increase (decrease) in cash and cash equivalents
-783 1,084
Cash and cash equivalents at beginning of period
3,025 -
Cash and cash equivalents at end of period
3,326 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics Inc. (DMAC)